On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may be the premier mRNA company with 43 developmental ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressured Regeneron from all-time highs, and the firm ...

On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte's ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm is acknowledges the potential for differentiation for ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following recent share pullback, a new management team, and robust ...

Occidental Petroleum (NYSE:OXY – Get Free Report) had its target price lifted by equities research analysts at Wolfe Research from $73.00 to $75.00 in a report released on Tuesday. The firm pres ...

On Thursday, Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), a leading bioprocessing company, with a Peerperform rating. The firm highlighted Repligen ...

On Thursday, Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN) Corporation (NASDAQ:RGEN), a leading bioprocessing company, with a Peerperform rating. The firm highlighted Repligen's ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.